Swedbank AB Has $8.04 Million Stock Position in Mineralys Therapeutics, Inc. $MLYS

Swedbank AB decreased its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 26.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 221,400 shares of the company’s stock after selling 77,900 shares during the period. Swedbank AB’s holdings in Mineralys Therapeutics were worth $8,035,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of MLYS. AQR Capital Management LLC acquired a new stake in shares of Mineralys Therapeutics in the first quarter worth $550,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Mineralys Therapeutics by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after acquiring an additional 702 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Mineralys Therapeutics by 166.6% in the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock worth $4,739,000 after acquiring an additional 186,480 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of Mineralys Therapeutics in the first quarter worth $757,000. Finally, Creative Planning acquired a new stake in shares of Mineralys Therapeutics in the second quarter worth $336,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. TD Cowen assumed coverage on shares of Mineralys Therapeutics in a research note on Monday, April 27th. They set a “buy” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Tuesday, April 21st. HC Wainwright set a $56.00 price target on shares of Mineralys Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Bank of America lifted their price target on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.14.

More Mineralys Therapeutics News

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Mineralys Therapeutics and a $56 price target, signaling continued long-term confidence even after trimming estimates. Source
• Neutral Sentiment: HC Wainwright still expects Mineralys to move toward profitability over time, projecting FY2029 EPS of $0.92 and FY2030 EPS of $3.73, although those forecasts were also reduced. Source
• Negative Sentiment: HC Wainwright cut near-term earnings estimates for Q2 2026, Q3 2026, and Q4 2026, suggesting a slower path to improvement in the company’s financial results. Source
• Negative Sentiment: The analyst also lowered longer-term estimates for FY2026, FY2027, and FY2028, which may weigh on investor sentiment around the stock’s valuation. Source
• Negative Sentiment: In a separate note, Wall Street Zen downgraded MLYS to “Sell”, adding to the bearish analyst tone surrounding the shares. Article

Insider Buying and Selling

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock in a transaction on Monday, April 13th. The stock was sold at an average price of $26.54, for a total transaction of $373,099.32. Following the completion of the transaction, the insider directly owned 76,140 shares of the company’s stock, valued at approximately $2,020,755.60. This trade represents a 15.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ra Capital Management, L.P. acquired 310,700 shares of the business’s stock in a transaction on Friday, March 27th. The shares were bought at an average cost of $23.67 per share, with a total value of $7,354,269.00. Following the completion of the acquisition, the director owned 5,767,221 shares of the company’s stock, valued at approximately $136,510,121.07. This trade represents a 5.69% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold a total of 162,291 shares of company stock valued at $4,336,414 in the last ninety days. Insiders own 18.94% of the company’s stock.

Mineralys Therapeutics Price Performance

MLYS opened at $29.54 on Friday. Mineralys Therapeutics, Inc. has a fifty-two week low of $12.59 and a fifty-two week high of $47.65. The firm’s fifty day moving average price is $27.15 and its two-hundred day moving average price is $33.14. The company has a market capitalization of $2.44 billion, a P/E ratio of -14.41 and a beta of 0.49.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04. On average, equities research analysts expect that Mineralys Therapeutics, Inc. will post -2.29 EPS for the current fiscal year.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.